Peter Greenleaf is CEO at Aurinia Pharmaceuticals Inc. (AUPH). They have made 9 open-market trades across 3 companies since 2016, most recently 2026-07-02.
CIK 0001363683
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $105K since 2018, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PTHS | SELL · 10b5-1 | 2026-07-02 | 2026-07-07 | $26.13 | $21K | +14.2% | +19.5% | -15.0% |
| PTHS | SELL · 10b5-1 | 2026-04-02 | 2026-04-06 | $20.92 | $17K | -8.0% | +0.0% | -2.0% |
| AUPH | SELL | 2025-03-03 | 2025-03-04 | $7.95 | $4.2M | +0.7% | -0.6% | -1.7% |
| AUPH | SELL | 2024-03-06 | 2024-03-07 | $5.60 | $1.4M | -5.1% | -8.8% | +0.0% |
| AUPH | SELL | 2023-03-02 | 2024-02-22 | $8.78 | $580K | -6.0% | -16.3% | -7.2% |
| AUPH | SELL | 2022-03-02 | 2022-03-04 | $12.01 | $218K | +2.7% | +15.7% | +2.9% |
| AUPH | BUY | 2021-05-11 | 2021-05-12 | $10.71 | $55K | +8.7% | +10.5% | +30.9% |
| CERC | BUY | 2018-05-18 | 2018-05-21 | $3.98 | $50K | +10.2% | +27.7% | +16.7% |
| SCMP | SELL | 2016-11-29 | 2016-11-30 | $16.75 | $1.4M | -6.7% | -17.1% | -28.1% |
| SCMP | SELL | 2016-11-28 | 2016-11-30 | $16.84 | $3.4M | -6.7% | -17.1% | -28.1% |
| SCMP | SELL | 2016-11-28 | 2016-11-30 | $16.91 | $2.0M | -6.7% | -17.1% | -28.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.